Ovation Science (OVAT) AI Stock Analysis

• Market Cap: C$881.12K
• Dividend Yield: N/A
• Average Volume (3M): 3.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -42.98%
• EPS Growth: 35.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 35,244,682
• 10 Day Avg. Volume: 3,400
• 30 Day Avg. Volume: 3,744
• PEG Ratio: 0.05
• Price to Book (P/B): -1.12
• Price to Sales (P/S): 10.81
• P/FCF Ratio: -6.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.03 ▼(-15.00% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily constrained by weak financial performance (ongoing losses, negative equity, and cash burn). Technical indicators add modest pressure with negative MACD and sub-50 RSI, while valuation remains unattractive due to loss-making status and no dividend support.

Positive Factors

Proprietary topical delivery platform

Ovation’s IntelliGel platform is a durable competitive asset: a technology backbone that can be applied across therapeutic and consumer skin-health products. A reproducible delivery platform supports licensing, partnerships, and product diversification, improving long-term revenue optionality and higher-margin opportunities.

Negative Factors

Persistent operating and net losses

Sustained operating and net losses plus recurring negative cash flow materially constrain strategic flexibility. Over multiple quarters this forces reliance on external financing, increases dilution risk, limits R&D or commercial investment, and undermines the company’s ability to achieve self-sustaining growth absent a structural business change.

Ovation Science Business Overview & Revenue Model

Company Description

Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing ...

Read more

Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing ...

How the Company Makes Money

Ovation Science generates revenue through the licensing and sale of its proprietary Invisicare technology to pharmaceutical and skincare companies. This technology is used to create more effective topical and transdermal products, enhancing the pe...

Read more

Ovation Science generates revenue through the licensing and sale of its proprietary Invisicare technology to pharmaceutical and skincare companies. This technology is used to create more effective topical and transdermal products, enhancing the pe...

Ovation Science Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	64.71K	113.22K	61.93K	138.15K	224.95K	750.01K
Gross Profit	58.31K	85.72K	-251.43K	134.11K	-168.75K	548.02K
EBITDA	-402.84K	-404.15K	-778.83K	-786.73K	-2.39M	-1.16M
Net Income	-459.50K	-456.20K	-813.15K	-794.05K	-2.39M	-1.18M
Balance Sheet
Total Assets	39.56K	63.90K	76.89K	104.89K	769.90K	3.25M
Cash, Cash Equivalents and Short-Term Investments	5.55K	3.31K	48.85K	28.90K	647.56K	1.54M
Total Debt	275.51K	268.48K	192.62K	41.13K	0.00	0.00
Total Liabilities	1.33M	1.15M	728.99K	187.84K	63.74K	143.38K
Stockholders Equity	-1.29M	-1.09M	-652.10K	-82.95K	706.15K	3.11M
Cash Flow
Free Cash Flow	7.08K	-178.82K	-336.02K	-670.80K	-885.75K	-1.52M
Operating Cash Flow	7.08K	-178.82K	-336.02K	-670.80K	-885.75K	-1.39M
Investing Cash Flow	0.00	0.00	0.00	0.00	1.16M	-685.18K
Financing Cash Flow	709.00	133.28K	356.16K	47.24K	0.00	2.05M

Ovation Science Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OVAT, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 6.97 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OVAT.

Ovation Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OILS	61 Neutral	C$8.44M	8.94	11.57%	―	-1.14%	―
VEXT	59 Neutral	C$65.64M	-6.17	-21.73%	―	43.56%	-349.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$59.88M	-6.23	-19.76%	―	26.91%	81.01%
LABS	49 Neutral	C$27.35M	-3.31	-19.10%	―	18.06%	34.58%
OVAT	43 Neutral	C$881.12K	-2.30	33.19%	―	-42.98%	35.33%
BNXT	42 Neutral	C$58.47M	-16.32	―	―	-62.34%	9.80%

Ovation Science Corporate Events